参考文献

1.Siegel RL，KD Miller，and A Jemal.Cancer Statistics，2017，CA Cancer JClin，2017，67（1）：7-30.

2.Ahn HS，HJ Kim，and HG Welch.Korea′s thyroid-cancer“epidemic”--screening and overdiagnosis.N Engl J Med，2014，371（19）：1765-1767.

3.董芬，张彪，单广良.中国甲状腺癌的流行现状和影响因素.中国癌症杂志，2016，1：47-52.

4.孙嘉伟，许晓君，蔡秋茂，等.中国甲状腺癌发病趋势分析.中国肿瘤，2013，22（9）：690-693.

5.Chen W，Zheng R，Baade PD，et al.Cancer statistics in China，2015，CA Cancer JClin，2016，66（2）：115-132.

6.Zheng R，Zeng H，Zhang S，et al.National estimates of cancer prevalence in China，2011，Cancer Lett，2016，370（1）：33-38.

7.Enewold L，Zhu K，Ron E，et al.Rising thyroid cancer incidence in the United States by demographic and tumor characteristics，1980-2005.Cancer Epidemiol Biomarkers Prev，2009，18（3）：784-791.

8.Ron E，Lubin JH，Shore RE，et al.Thyroid cancer after exposure to external radiation：a pooled analysis of seven studies.Radiat Res，1995，141（3）：259-277.

9.Veiga LH，Lubin JH，Anderson H，et al.A pooled analysis of thyroid cancer incidence following radiotherapy for childhood cancer.Radiat Res，2012，178（4）：365-376.

10.Foley TP，Z.Limanova，and E Potlukova，Medical consequences of Chernobyl with focus on the endocrine system：Part1.Cas Lek Cesk，2015，154（5）：227-231.

11.Cardis E，Howe G，Ron E，et al.Cancer consequences of the Chernobyl accident：20 years on.J Radiol Prot，2006，26（2）：127-140.

12.Memon A，Godward S，Williams D，et al.Dental x-rays and the risk of thyroid cancer：a case-control study.Acta Oncol，2016，49（4）：447-453.

13.Richardson DB.Exposure to ionizing radiation in adulthood and thyroid cancer incidence.Epidemiology，2009，20（2）：181-187.

14.Negri E，Dal Maso L，Ron E，et al.A pooled analysis of case-control studies of thyroid cancer.II.Menstrual and reproductive factors.Cancer Causes Control，1999，10（2）：143-155.

15.马洁，关海霞.妊娠与甲状腺癌关联的研究进展.中华内分泌代谢杂志，2014，30（12）：1132-1134.

16.Franceschi S，Preston-Martin S，Dal Maso L，et al.A pooled analysis of case-control studies of thyroid cancer.IV.Benign thyroid diseases.Cancer Causes Control，1999，10（6）：583-595.

17.Pita JM，Figueiredo IF，Moura MM，et al.Cell cycle deregulation and TP53 and RASmutations aremajor events in poorly differentiated and undifferentiated thyroid carcinomas.JClin Endocrinol Metab，2014，99（3）：E497-507.

18.Hanahan D and RAWeinberg.Hallmarks of cancer：the next generation.Cell，2011，144（5）：646-674.

19.Fiore E，Rago T，Provenzale MA，et al.Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease：thyroid autonomy may play a protective role.Endocr Relat Cancer，2009，16（4）：1251-1260.

20.Hatch，M，Furukawa K，Brenner A，et al.Prevalence of hyperthyroidism after exposure during childhood or adolescence to radioiodines from the chornobyl nuclear accident：doseresponse results from the Ukrainian-American Cohort Study.Radiat Res，2010，174（6）：763-772.

21.Singh，B，Shaha AR，Trivedi H，et al.Coexistent Hashimoto′s thyroiditis with papillary thyroid carcinoma：impact on presentation，management，and outcome.Surgery，1999，126（6）：1070-1076；discussion 1076-1077.

22.Kim KW，Park YJ，Kim EH，et al.Elevated risk of papillary thyroid cancer in Korean patientswith Hashimoto′s thyroiditis.Head Neck，2011，33（5）：691-695.

23.Larson SD，Jackson LN，Riall TS，et al.Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Aktpathway.JAm Coll Surg，2007，204（5）：764-773；discussion 773-775.

24.Mechler C，Bounacer A，Suarez H，et al.Papillary thyroid carcinoma：6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements.Br J Cancer，2001，85（12）：1831-1837.

25.Anderson CE，Graham C，Herriot MM，et al.CD98 expression is decreased in papillary carcinoma of the thyroid and Hashimoto′s thyroiditis.Histopathology，2009，55（6）：683-686.

26.Wirtschafter A，Schmidt R，Rosen D，et al.Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto′s thyroiditis.Laryngoscope，1997，107（1）：95-100.

27.Royer MC，Zhang H，Fan CY，et al.Genetic alterations in papillary thyroid carcinoma and hashimoto thyroiditis：An analysis of hOGG1 loss of heterozygosity.Arch Otolaryngol Head Neck Surg，2016，136（3）：240-242.

28.Bosetti C，Kolonel L，Negri E，et al.A pooled analysis of case-control studies of thyroid cancer.VI.Fish and shellfish consumption.Cancer Causes Control，2001，12（4）：375-382.

29.Bosetti C，Negri E，Kolonel L，et al.A pooled analysis of case-control studies of thyroid cancer.Ⅶ.Cruciferous and other vegetables（International）.Cancer Causes Control，2002，13（8）：765-775.

30.Zimmermann MB and V Galetti.Iodine intake as a risk factor for thyroid cancer：a comprehensive review of animal and human studies.Thyroid Res，2015，8：8.

31.Kanno J，Onodera H，Furuta K，et al.Tumor-promoting effects of both iodine deficiency and iodine excess in the rat thyroid.Toxicol Pathol，1992，20（2）：226-235.

32.Boltze C，Brabant G，Dralle H，et al.Radiation-induced thyroid carcinogenesis as a function of time and dietary iodine supply：an in vivomodel of tumorigenesis in the rat.Endocrinology，2002，143（7）：2584-2592.

33.Chen Z，Xu W，Huang Y，et al.Associations of noniodized salt and thyroid nodule among the Chinese population：a large cross-sectional study.Am JClin Nutr，2013，98（3）：684-692.

34.Teng W，Shan Z，Teng X，et al.Effect of iodine intake on thyroid diseases in China.N Engl JMed，2006，354（26）：2783-2793.

35.竺王玉，刘晓光，胡晓斐，等.舟山群岛居民碘营养状况及甲状腺癌现患调查.卫生研究，2012，41（1）：79-82.

36.Xu L，PortM，Landi S，etal.Obesity and the risk of papillary thyroid cancer：a pooled analysis of three case-control studies.Thyroid，2014，24（6）：966-974.

37.Bhaskaran K，Douglas I，Forbes H，et al.Body-mass index and risk of 22 specific cancers：a population-based cohort study of5.24million UK adults.Lancet，2014，384（9945）：755-765.

38.Khan A，Smellie J，Nutting C，et al.Familial nonmedullary thyroid cancer：a review of the genetics.Thyroid，2016，20（7）：795-801.

39.American Thyroid Association Guidelines Task.Medullary thyroid cancer：management guidelines of the American Thyroid Association.Thyroid，2009，19（6）：565-612.

40.Navas-Carrillo D，Ríos A，Rodríguez JM，et al.Familial nonmedullary thyroid cancer：screening，clinical，molecular and genetic findings.Biochim Biophys Acta，2014，1846（2）：468-476.

41.Charkes ND.On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds.Thyroid，2006，16（2）：181-186.

42.Tang KT and CH Lee.BRAF mutation in papillary thyroid carcinoma：pathogenic role and clinical implications.JChin Med Assoc，2010，73（3）：113-128.

43.Xing M.BRAF mutation in thyroid cancer.Endocr Relat Cancer，2005，12（2）：245-262.

44.Chiosea S，Nikiforova M，Zuo H，et al.A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma.Endocr Pathol，2009，20（2）：122-126.

45.Ciampi R，Knauf JA，Kerler R，et al.Oncogenic AKAP9-BRAF fusion is a novelmechanism of MAPK pathway activation in thyroid cancer.J Clin Invest，2005，115（1）：94-101.

46.只璟泰，郑向前，高明.甲状腺癌相关基因研究进展.中华耳鼻咽喉头颈外科杂志，2016，51（12）：951-955.

47.Nikiforova MN and YE Nikiforov，Molecular diagnostics and predictors in thyroid cancer.Thyroid，2009，19（12）：1351-1361.

48.Motoi N，Sakamoto A，Yamochi T，et al.Role of rasmutation in the progression of thyroid carcinoma of follicular epithelial origin.Pathol Res Pract，2006，196（1）：1-7.

49.Schulten HJ，Salama S，Al-Ahmadi A，et al.Comprehensive survey of HRAS，KRAS，and NRASmutations in proliferative thyroid lesions from an ethnically diverse population.Anticancer Res，2013，33（11）：4779-4784.

50.Esapa CT，Johnson SJ，Kendall-Taylor P，etal.Prevalence of Ras mutations in thyroid neoplasia.Clin Endocrinol（Oxf），1999，50（4）：529-535.

51.Kroll TG，Sarraf P，Pecciarini L，et al.PAX8-PPARgammal fusion oncogene in human thyroid carcinoma.Science，2006，289（5483）：1357-1360.

52.Eberhardt NL，Grebe SK，McIver B，et al.The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer.Mol Cell Endocrinol，2016，321（1）：50-56.

53.Castro P，Rebocho AP，Soares RJ，et al.PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma.J Clin Endocrinol Metab，2006，91（1）：213-220.

54.Marques AR，Espadinha C，Catarino AL，et al.Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas.JClin EndocrinolMetab，2002，87（8）：3947-3952.

55.Armstrong MJ，Yang H，Yip L，et al.PAX8/PPARgamma rearrangement in thyroid nodules predicts follicular-pattern carcinomas，in particular the encapsulated follicular variant of papillary carcinoma.Thyroid，2014，24（9）：1369-1374.

56.Grieco M，Santoro M，Berlingieri MT，et al.PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas.Cell，1990，60（4）：557-563.

57.Santoro M，Dathan NA，Berlingieri MT，et al.Molecular characterization of RET/PTC3；a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma.Oncogene，1994，9（2）：509-516.

58.Ciampi R，Giordano TJ，Wikenheiser-Brokamp K，et al.HOOK3-RET：a novel type of RET/PTC rearrangement in papillary thyroid carcinoma.Endocr Relat Cancer，2007，14（2）：445-452.

59.Rabes HM，Demidchik EP，Sidorow JD，et al.Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas：biological，phenotypic，and clinical implications.Clin Cancer Res，2000，6（3）：1093-1103.

60.Fenton CL，Lukes Y，Nicholson D，et al.The ret/PTCmutations are common in sporadic papillary thyroid carcinoma of children and young adults.JClin Endocrinol Metab，2000，85（3）：1170-1175.

61.杨旭辉，甲状腺癌分子标记物的研究进展.临床与病理杂志，2015（6）：1148-1156.

62.Horn S，Figl A，Rachakonda PS，et al.TERT promotermutations in familial and sporadicmelanoma.Science，2013，339（6122）：959-961.

63.Liu X，Qu S，Liu R，et al.TERT promoter mutations and their association with BRAFV600E mutation and aggressive clinicopathological characteristics of thyroid cancer.J Clin Endocrinol Metab，2014，99（6）：E1130-1136.

64.Muzza M，Colombo C，Rossi S，et al.Telomerase in differentiated thyroid cancer：promotermutations，expression and localization.Mol Cell Endocrinol，2015，399：288-295.

65.张磊，李小毅，端粒酶反转录酶启动子突变在甲状腺癌中的研究进展.癌症进展，2015（4）：391-395，456.

66.Putti TC and TA Bhuiya.Mixed columnar cell and tall cell variant of papillary carcinoma of thyroid：a case report and review of the literature.Pathology，2006，32（4）：286-289.

67.Boufraqech MJ，Klubo-Gwiezdzinska and E Kebebew.MicroRNAs in the thyroid.Best Pract Res Clin Endocrinol Metab，2016，30（5）：603-619.

68.Saltman B，Singh B，Hedvat CV，et al.Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression.Surgery，2006，140（6）：899-905；discussion 905-906.

69.Jazdzewski K，Murray EL，Franssila K，et al.Common SNP in pre-miR-146a decreases maturemiR expression and predisposes to papillary thyroid carcinoma.Proc Natl Acad Sci U SA，2008，105（20）：7269-7274.

70.Dong S，Jin M，Li Y，etal.MiR-137 acts as a tumor suppressor in papillary thyroid carcinoma by targeting CXCL12.Oncol Rep，2016，35（4）：2151-2158.

71.Minna E，Romeo P，Dugo M，et al.miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.Oncotarget，2016，7（11）：12731-12747.

72.Hemminki K and X Li.Familial risk of cancer by site and histopathology.Int JCancer，2003，103（1）：105-109.

73.高明，于洋，赵静，遗传性甲状腺癌.外科理论与实践，2012，17（1）：7-10.

74.Cao J，Chen C，Chen C，et al.Clinicopathological features and prognosis of familial papillary thyroid carcinoma--a large-scale，matched，case-control study.Clin Endocrinol（Oxf），2016，84（4）：598-606.

75.Robenshtok E，Tzvetov G，Grozinsky-Glasberg S，et al.Clinical characteristics and outcome of familial nonmedullary thyroid cancer：a retrospective controlled study.Thyroid，2011，21（1）：43-48.

76.Cetta F，Montalto G，GoriM，etal.Germlinemutations of the APC gene in patients with familial adenomatous polyposisassociated thyroid carcinoma：results from a European cooperative study.J Clin Endocrinol Metab，2006，85（1）：286-292.

77.Liaw D，Marsh DJ，Li J，et al.Germline mutations of the PTEN gene in Cowden disease，an inherited breast and thyroid cancer syndrome.Nat Genet，1997，16（1）：64-67.

78.Stratakis CA，Courcoutsakis NA，Abati A，et al.Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation，myxomas，endocrine overactivity，and schwannomas（Carney complex）.JClin Endocrinol Metab，1997，82（7）：2037-2043.

79.Malchoff CD and DM Malchoff.The genetics of hereditary nonmedullary thyroid carcinoma.JClin Endocrinol Metab，2002，87（6）：2455-2459.

80.Malchoff CD and DM Malchoff.Familial nonmedullary thyroid carcinoma.Cancer Control，2006，13（2）：106-110.

81.Kebebew E.Hereditary non-medullary thyroid cancer.World JSurg，2008，32（5）：678-682.

82.Bignell GR，Canzian F，Shayeghi M，et al.Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer.Am JHum Genet，1997，61（5）：1123-1130.

83.Malchoff CD，SarfaraziM，Tendler B，et al.Papillary thyroid carcinoma associated with papillary renal neoplasia：genetic linkage analysis of a distinct heritable tumor syndrome.J Clin Endocrinol Metab，2006，85（5）：1758-1764.

84.Lesueur F，Stark M，Tocco T，et al.Genetic heterogeneity in familial nonmedullary thyroid carcinoma：exclusion of linkage to RET，MNG1，and TCO in 56 families.NMTCConsortium.JClin Endocrinol Metab，1999，84（6）：2157-2162.

85.McKay JD，Williamson J，Lesueur F，et al.At least three genes account for familial papillary thyroid carcinoma：TCO and MNG1 excluded as susceptibility loci from a large Tasmanian family.Eur JEndocrinol，1999，141（2）：122-125.

86.Suh I，Filetti S，VriensMR，et al.Distinct locion chromosome 1q21 and 6q22 predispose to familial nonmedullary thyroid cancer：a SNP array-based linkage analysis of 38 families.Surgery，2009，146（6）：1073-1080.

87.Cavaco BM，Batista PF，Martins C，et al.Familial non-medullary thyroid carcinoma（FNMTC）：analysis of fPTC/PRN，NMTC1，MNG1 and TCO susceptibility loci and identification of somatic BRAF and RASmutations.Endocr Relat Cancer，2008，15（1）：207-215.

88.Canzian F，Amati P，Harach HR，et al.A gene predisposing to familial thyroid tumors with cell oxyphiliamaps to chromosome 19p13.2.Am J Hum Genet，1998，63（6）：1743-1748.

89.Bonora E，Evangelisti C，Bonichon F，et al.Novel germline variants identified in the inner mitochondrial membrane transporter TIMM44 and their role in predisposition to oncocytic thyroid carcinomas.Br J Cancer，2006，95（11）：1529-1536.

90.Bevan S，Pal T，Greenberg CR，et al.A comprehensive analysis ofMNG1，TCO1，fPTC，PTEN，TSHR，and TRKA in familial nonmedullary thyroid cancer：confirmation of linkage to TCO1.J Clin Endocrinol Metab，2001，86（8）：3701-3704.

91.Prazeres HJ，Rodrigues F，Soares P，et al.Loss of heterozygosity at 19p13.2 and 2q21 in tumours from familial clusters of non-medullary thyroid carcinoma.Fam Cancer，2008，7（2）：141-149.

92.McKay JD，Thompson D，Lesueur F，et al.Evidence for interaction between the TCO and NMTC1 loci in familial nonmedullary thyroid cancer.J Med Genet，2004，41（6）：407-412.

93.Capezzone M，Cantara S，Marchisotta S，et al.Short telomeres，telomerase reverse transcriptase gene amplification，and increased telomerase activity in the blood of familial papillary thyroid cancer patients.J Clin Endocrinol Metab，2008，93（10）：3950-3957.

94.Cavaco BM，Batista PF，Sobrinho LG，et al.Mapping a new familial thyroid epithelial neoplasia susceptibility locus to chromosome 8p23.1-p22 by high-density single-nucleotide polymorphism genome-wide linkage analysis.J Clin Endocrinol Metab，2008，93（11）：4426-4430.

95.Tsilchorozidou T，Vafiadou E，Yovos JG，etal.AGreek family with a follicular variant of familial papillary thyroid carcinoma：TCO，MNG1，fPTC/PRN，and NMTC1 excluded as susceptibility loci.Thyroid，2005，15（12）：1349-1354.

96.Bauer AJ.Clinical behavior and genetics of nonsyndromic，familial nonmedullary thyroid cancer.Front Horm Res，2013，41：141-148.

97.Raue F and K Frank-Raue，Genotype-phenotype relationship in multiple endocrine neoplasia type 2.Implications for clinicalmanagement.Hormones（Athens），2009，8（1）：23-28.

98.Jasim S，Ying AK，Waguespack SG，etal.Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883Fmutation displays amore indolent form of medullary thyroid carcinoma compared with a RET M918T mutation.Thyroid，2011，21（2）：189-192.